Ichnos Glenmark Innovation
NY - New York
ALYACEN 1/35 (norethindrone and ethinyl estradiol) by Ichnos Glenmark Innovation is clinical pharmacology combined oral contraceptives combined oral contraceptives act by suppression of gonadotropins. Approved for pregnancy in women. First approved in 2012.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Combined Oral Contraceptives Combined oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into…
A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women
Worked on ALYACEN 1/35 at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.